Notícias

With a 5-year average revenue growth rate of 13.52%, Boston Scientific Corporation (NASDAQ:BSX) is included among the 11 Best Long Term US Stocks to Buy Right Now. On May 19, Baird lowered its price recommendation on Boston Scientific Corporation (NASDAQ:BSX) to $75 from $78. It reiterated an Outperform rating on the shares. The firm updated its model […]

Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index and the State Street H

Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 1.1% and the State S

Boston Scientific (BSX) stock declined 47% over the last 12 months to trade near $57. Despite total revenues growing 17.4% to $20.6 billion and net income margins improving to 17.3%, the P/E multiple contracted by 70%. The selloff was triggered by a Q4 2025 GAAP EPS miss and a significant full-year 2026 organic growth guidance cut. The company's management lowered the target from a 10 to 11% range down to 6.5 to 8.0%, attributing the reset to greater-than-expected market share loss in the Electr

Boston Scientific plans to use the IDE trials results to support a regulatory filing of its Seismiq 4CE Coronary catheter with the FDA.

According to the average brokerage recommendation (ABR), one should invest in Boston Scientific (BSX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Companies In The Article Are:REGN,D,NEE,STX and BSX

With the study results, Boston Scientific plans a regulatory submission for the intravascular lithotripsy treatment for patients with severely calcified coronary artery disease.

Boston Scientific may acquire full ownership of MiRus’ TAVR business for an additional $3bn after achieving certain milestones.

Boston Scientific (NYSE:BSX) announced a US$2b accelerated share repurchase program. The company also agreed to invest US$1.5b in MiRus, securing a significant equity stake. The MiRus deal includes an exclusive option related to the company’s transcatheter aortic valve replacement (TAVR) business. Boston Scientific, a large medical device company focused on cardiovascular and other interventional therapies, is pairing a sizeable capital return with a move deeper into structural heart...

The S&P 500 Index ($SPX ) (SPY ) on Monday closed down -0.07%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.32%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.45%. June E-mini S&P futures (ESM26 ) fell -0.12%, and June E-mini Nasdaq futures...

Healthcare stocks rose late Monday afternoon, with the NYSE Healthcare Index and the State Street He

The deal gives Boston Scientific a 34% stake in MiRus and an option to buy its TAVR business for an additional $3 billion

BSX expands into fast-growing medtech segments with acquisitions spanning urology, pain management and vascular devices.

(Bloomberg) -- For years, there was only one way for mom-and-pop investors to buy into Elon Musk’s vision: shares of Tesla Inc. That’s about to change — and it’s a serious risk for Tesla investors. Most Read from BloombergStocks Fall, Oil Rises as Hormuz Deal Hopes Fade: Markets WrapBillionaire Rinehart Bets $100 Million on US Defense StocksIranian Media Said US Offered Interim Waiver on Oil SanctionsUS and Iran Far From Deal as Bond Rout Piles Pressure on TrumpWinners and Losers From Trump and

Stock Gains Following Capital Allocation AnnouncementsShares of Boston Scientific (NYSE:BSX) rose 2. 1% in premarket trading on Monday after the company announced a $2 billion accelerated share repurchase program alongside a $1.

Healthcare stocks were declining pre-bell Monday, with the State Street Health Care Select Sector SP

The deal gives Boston Scientific a 34% equity stake in MiRus and an option to acquire its TAVR platform by making additional payments totaling $3 billion.

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.

Moby summary of Elutia Inc.'s Q1 2026 earnings call

BSX expands global reach with strong APAC growth, FARAPULSE momentum and new approvals driving gains across Europe and China.

Boston Scientific Corporation (NYSE:BSX) was one of the stocks on which Jim Cramer shared his take, explaining that dot-com analogies do not hold up in this market. During the lightning round, a caller asked if they should sell or buy more BSX shares. Cramer replied: I hate to sell these. I don’t mean to sound […]

Danaher Corporation (NYSE:DHR) was one of the stocks on which Jim Cramer shared his take, explaining that dot-com analogies do not hold up in this market. Cramer called it a “one-time excellent company,” as he said: For instance, Danaher, another one-time excellent company, has seen the stock just get pulverized after not-so-great quarters, or I […]

Aristotle Capital Management, LLC, an investment management company, released its “Core Equity Fund” first-quarter 2026 investor letter. A copy of the letter can be downloaded here. During the first quarter, the U.S. equity market declined, with the S&P 500 Index falling by 4.33%. The fixed-income sector also saw a downturn; the Bloomberg U.S. Aggregate Bond Index […]

Earlier in May 2026, Boston Scientific filed a US$565.7 million shelf registration for up to 10,000,000 common shares tied to an ESOP-related offering, while shareholders also approved charter amendments eliminating supermajority voting and adding limited officer exculpation under Delaware law. Taken together with recent director equity and deferred stock awards, these developments highlight a stronger emphasis on ownership-based incentives and refreshed corporate governance at the...

Morningstar now rates Boston Scientific (BSX) as significantly undervalued after a meaningful share price decline. The firm is flagging the stock as a potential opportunity for investors who focus on gaps between price and estimated fair value. See our latest analysis for Boston Scientific. Recent governance updates, including the removal of supermajority voting provisions and fresh director equity awards, have coincided with a sharp reset in sentiment, with the 30 day share price return down...

Boston Scientific rides on cardiovascular device growth with FARAPULSE and WATCHMAN momentum, but margin pressure and weaker estimates cloud the outlook.

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended holding Boston Scientific Corporation. “I don't understand how this thing could have fallen so fast,” he said of the medical device maker. “I know there's a lot of competition. I don't...

The latest generation of the coronary intravascular lithotripsy device is designed to be more flexible to help physicians navigate tight arteries to break up calcified deposits and restore blood flow.

Boston Scientific Corporation ( NYSE:BSX ) shareholders might have a reason to worry after multiple insiders sold their...